InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights PC111 Breakthrough After Scientist Wins Top Italian Dermatology Award
June 26, 2025
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology, announced that Dr. Roberta Lotti of Pincell Srl has won the “Oscar of Italian Dermatology” from SIDeMaST for her research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The study, published under the title “Blocking soluble Fas Ligand ameliorates pemphigus”, confirms PC111’s ability […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights Growth and SEPA Funding Ahead of BIO 2025 CEO Participation
June 12, 2025
Scinai Immunotherapeutics (NASDAQ: SCNI) announced that CEO Amir Reichman will participate in the BIO International Convention 2025, taking place June 16–19 in Boston. The company will present recent strategic, operational, and financial milestones, including its rapid CDMO business growth and progress on its nanobody pipeline. Scinai recently secured $1.38 million in funding via its Standby […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Italian Clearance for Option to Acquire Biotech Firm Pincell
June 5, 2025
Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has received regulatory clearance under Italy’s Golden Power regulation to proceed with its option to acquire 100% of Pincell S.r.l., an Italian biotech company. The approval, issued by Italy’s Coordination Group and Ministry of Health, supports Scinai’s strategic move to expand its inflammation and immunology pipeline. Pincell’s lead asset, […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q1 Revenue Growth Driven by CDMO Contracts, Net Loss Narrows
May 30, 2025
Scinai Immunotherapeutics (NASDAQ: SCNI) reported first quarter 2025 financial results, posting $586K in revenue, up from zero in the prior-year period, reflecting continued expansion of its CDMO business. R&D expenses declined to $1.3M from $1.6M, while marketing, general and administrative costs held steady at $500K. The company recorded a $1.6M net loss, improving from a […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports $4.8 Million Net Gain in 2024, Driven by Loan-to-Equity Conversion
May 8, 2025
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology treatments and CDMO services, reported a $4.8 million net gain for 2024, reversing a $6.5 million loss in 2023. The improvement was largely due to $14.8 million in financial income from a loan-to-equity conversion. The company posted $658,000 in revenue—its first ever—from its CDMO […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders
May 1, 2025
Scinai Immunotherapeutics (NASDAQ: SCNI) will host a webinar May 7 at 11:30 a.m. EST to discuss the treatment potential of Pincell’s novel monoclonal antibody, PC111, for rare skin conditions Pemphigus Vulgaris and SJS/TEN. The session will cover unmet medical needs, PC111’s mechanism targeting soluble Fas ligand, and development plans. The event follows Scinai’s March agreement […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell
March 27, 2025
Scinai Immunotherapeutics (NASDAQ: SCNI), announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing PC111, a first-in-class antibody targeting severe skin blistering disorders. In tandem, Scinai’s Polish subsidiary submitted a €12 million non-dilutive grant application under the EU’s FENG program to fund the next development phase of PC111. The […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Present at BIO-Europe Spring 2025
March 17, 2025
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, announced its participation in the BIO-Europe Spring 2025 conference from March 17-19 in Milan, Italy. The company’s leadership will meet with potential pharmaceutical partners, prospective CDMO clients, and institutional investors to showcase its […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters $10 Million Standby Equity Purchase Agreement
March 5, 2025
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on inflammation and immunology biological products and contract development and manufacturing organization (CDMO) services, has entered into a standby equity purchase agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors Global. The agreement allows Scinai to sell up to $10 million of its American Depository […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Engage Investors and Partners at Key January Conferences
January 6, 2025
Scinai Immunotherapeutics (NASDAQ: SCNI) a biopharmaceutical company focused on inflammation and immunology products and CDMO services, announced CEO Amir Reichman and Chairman Mark Germain will participate in several high-profile events in January 2025. They will attend the IATI Mini Mixiii Conference in Miami on January 9, followed by the JP Morgan HealthCare Conference and SIC […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary
December 16, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI) has established a U.S.-based subsidiary, Scinai Bioservices Inc., to enhance its Contract Development and Manufacturing Organization (CDMO) operations and address the growing demand for early-stage biologics development in the U.S. Operating from a cGMP-compliant facility in Jerusalem, Israel, Scinai Bioservices has supported nine biotech companies since its 2024 launch and recently […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Strategic Board Appointment
December 5, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in the development of inflammation and immunology (“I&I”) biological products and offering CDMO services through its Scinai Bioservices unit, today announced the appointment of Prof. Michael Schön to its Scientific Advisory Board (“SAB”). Recognized with numerous awards for his groundbreaking research on immune reactions in inflammation, Prof. […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board
November 27, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI) has appointed Dr. Jonathan Sadeh to its Scientific Advisory Board, where he will support the advancement of the company’s IL-17 program and VHH antibody pipeline. Dr. Sadeh brings over 20 years of drug development experience, including senior leadership roles at Bristol-Myers Squibb, where he led programs in immunology, cardiovascular, and neuroscience, […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Nine-Month Financial Results and Business Update
November 22, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing innovative biological products targeting inflammation and immunology (“I&I”) and offering contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices division, released its financial results for the nine months ending Sept. 30, 2024. The announcement highlights the company’s progress in advancing its I&I-focused pipeline […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Spotlight Innovative I&I Pipeline and CDMO Services at BIO-Europe 2024
October 31, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI) will showcase its inflammation and immunology (“I&I”) product pipeline and contract development and manufacturing (“CDMO”) services at the BIO-Europe 2024 conference in Stockholm from November 4-6. CEO Amir Reichman and CTO Dr. Dalit Weinstein-Fischer will meet with potential clients, pharma partners and investors to discuss co-development opportunities in I&I, collaborations in […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution
September 16, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced plans to host a scientific webinar to discuss the plaque psoriasis landscape, current treatment methods, and existing unmet needs in treating mild to moderate plaque psoriasis. The […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
September 9, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is spotlighted in this week’s episode of The BioMedWire Podcast. During the episode, Scinai Immunotherapeutics CEO Amir Reichman talks with host Carmel Fisher about SCNI’s […]
IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.
September 9, 2024
LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) — via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast features fast-paced interviews […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), EIB Close on Loan Restructuring Agreement
August 21, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has closed on its previously announced loan restructuring agreement. According to the announcement, the agreement is with the European Investment Bank (“EIB”) and includes […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
August 20, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, has entered into a $2 million Investment Commitment Agreement with RK Stone Miami LLC, an affiliate of the largest shareholder of the company, Mr. Daniel Stone. Under the terms […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update
August 15, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today published its financial results for the second quarter ended June 30, 2024, and provided a business update. Scinai plans to host a webinar to discuss […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity
August 13, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the signing of a definitive Loan Restructuring Agreement with the European Investment Bank (“EIB”), its lender. The agreement also included an amendment and restatement to the Finance […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives PEI Feedback Regarding Development, Preclinical Trial of Anti-IL-17 NanoAb
July 23, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has received the minutes of meeting from a recent Scientific Advice (“SA”) with the Paul Erlich Institute, Federal Institute for Vaccines and Biomedicines (“PEI”). […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study
July 15, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting recent study results. According to the announcement, the successful in-vivo preclinical results are from SCNI’s innovative anti IL-17A/F VHH antibody fragment (“NanoAb”), […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Updated LoI from the European Investment Bank
July 8, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced its receipt of an updated non-binding letter of intent (“LoI”) from the European Investment Bank (“EIB”). The updated LoI outlines specific terms for converting the majority […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q1 2024 Financial Reports, Business Update
July 2, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting on its financial results for the quarter ended March 31, 2024; the company also released a business update. Notable financial numbers include […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion
June 13, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has received a nonbinding letter of intent (“LOI”) from the European Investment Bank (“EIB”). According to the announcement, the LOI contains terms for […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Regains Compliance with Nasdaq Listing Rule 5550(a)(2)
June 7, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company announced today that on June 5, 2024, it received a formal notification from the Listing Qualification Department of the Nasdaq Stock Market that it has regained […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases FY 2023 Financial Results, Provides Business Update
May 16, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting its full-year financial results for 2023 along with a company update. Highlights of the report included news that, in the first […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Nasdaq Delisting Notification and Appeal, ADS Ratio Change
May 6, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today announced that it has received a staff determination letter on April 30, 2024, from the Listing Qualifications Department of the Nasdaq Stock Market LLC. In […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Chief Science Officer to Present at This Month’s Europe Dermatology Drug Development Summit
April 10, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, will be featured at this month’s annual Dermatology Drug Development Summit Europe. During the three-day gathering, SCNI chief science officer Dr. Tamar Ben-Yedidia will discuss […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma
April 8, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, through its contract development and manufacturing organization (“CDMO”) business unit, Scinai Bioservices, has signed a five-year Master Service Agreement (“MSA”) with Ayana Pharma Ltd. As outlined by the MSA, Scinai will provide drug-development and cGMP manufacturing services to Ayana; the […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024
March 12, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, will be participating at this month’s BIO-Europe Spring 2024 conference. The conference is scheduled for March 18–20, 2024, in Barcelona. According to the announcement, Scinai management will be […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Planned Participation at MIXiii 2024, Bio Europe Spring Conference
February 29, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced that it will be attending the MIXiii International Life Science and Health-tech Conference. The event is slated to take place March 5 and 6 in Jerusalem. Several […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales
February 13, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as head of business development and sales. Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Scientific Research Collaborator Receives Prestigious Louis-Jeantet Prize
January 25, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, is congratulating its colead scientific research collaborator Professor Dr. Dirk Görlich, who is this year’s Louis-Jeantet Prize recipient. A director at the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”), Görlich and his colleague Dr. Matthias Dobbelstein, from the University Medical Center Göttingen (“UMG”), […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Closes on $1.69M Exercise of Outstanding Warrants
January 5, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (“I&I”) biological therapeutic products and provision of boutique CDMO services, has closed on its previously announced exercise of certain outstanding warrants. The exercise involved the purchase of up to 2,606,552 American Depositary Shares (“ADSs”), with each share representing 400 ordinary shares. […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Releases Shareholder Letter
January 4, 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (“I&I”) biological products, has released a letter from its CEO, Amir Reichman. In the letter, Reichman summarizes the company’s 2023 accomplishments and looks forward to 2024. According to the letter, company highlights for the year include a recently completed ex-vivo study that indicates the potential […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Agreement for Million-Dollar Exercise of Outstanding Warrants
December 29, 2023
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products and provision of boutique CDMO (“CDMO”) services, has entered a definitive agreement for the immediate exercise of outstanding warrants. The agreement outlines the purchase of up to 2,606,552 American Depositary Shares (“ADSs”), with each ADS representing […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces January Analyst, Investor Webinar
December 27, 2023
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of both inflammation and immunology. During the webinar, SCNI CEO Amir Reichman will present an overview of the company’s performance throughout the year 2023, along with a discussion of the company’s upcoming plans for 2024. Specifically Reichman will discuss the company’s plan to commence clinical trials […]